Inflammatory processes in Alzheimer's disease

Journal of Neuroimmunology

Volumn 184, Issue 1-2, 2007, Pages 69-91

  Heneka, Michael T ^a,b   O'Banion, M Kerry ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Amyloid; Astrocyte; Cytokine; Innate immunity; Microglia; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; CHEMOKINE; CHROMOGRANIN A; CYTOKINE; FLURBIPROFEN; FREE RADICAL; IBUPROFEN; INDOMETACIN; NAPROXEN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN SYNTHASE; PROSTANOID;

ALZHEIMER DISEASE; ASTROCYTE; CLINICAL TRIAL; COMPLEMENT SYSTEM; DIABETES MELLITUS; FEEDBACK SYSTEM; FOREBRAIN; HUMAN; INFLAMMATION; LOCUS CERULEUS; MICROGLIA; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEUROGLIA; NEURONS;

EID: 33847613885     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.11.017     Document Type: Review

References (324)

1. Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., Morris C., Winblad B., Nordberg A., and Zhu J. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice. J. Neuroimmunol. 126 (2002) 50-57
2. Adolfsson R., Gottfries C.G., Roos B.E., and Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry 135 (1979) 216-223
3. Agdeppa E.D., Kepe V., Petri A., Satyamurthy N., Liu J., Huang S.C., Small G.W., Cole G.M., and Barrio J.R. In vitro detection of S-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-1-[6-[2-[18F]fluoroethylmethylamino]-2-naphthyl]ethylidenemalono nitrile. Neuroscience 117 (2003) 723-730
4. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., and Thal L.J. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (2003) 2819-2826
5. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383-421
6. Alafuzoff I., Overmyer M., Helisalmi S., and Soininen H. Lower counts of astroglia and activated microglia in patients with Alzheimer's disease with regular use of non-steroidal anti-inflammatory drugs. J. Alzheimer's Dis. 2 (2000) 37-46
7. Almer G., Vukosavic S., Romero N., and Przedborski S. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 72 (1999) 2415-2425
8. Aloisi F., Care A., Borsellino G., Gallo P., Rosa S., Bassani A., Cabibbo A., Testa U., Levi G., and Peschle C. Production of hemolymphopoietic cytokines Il-6, Il-8, colony-stimulating factors by normal human astrocytes in response to Il-1-beta and tumor-necrosis-factor-alpha. J. Immunol. 149 (1992) 2358-2366
9. Amara F.M., Junaid A., Clough R.R., and Liang B.H. TGF-beta1, regulation of Alzheimer amyloid precursor protein mRNA expression in a normal human astrocyte cell line: mRNA stabilization. Mol. Brain Res. 71 (1999) 42-49
10. Anthony J.C., Breitner J.C., Zandi P.P., Meyer M.R., Jurasova I., Norton M.C., and Stone S.V. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54 (2000) 2066-2071
11. Apelt R., and Schliebs J. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 894 (2001) 21-30
12. Bach J.H., Chae H.S., Rah J.C., Lee M.W., Park C.H., Choi S.H., Choi J.K., Lee S.H., Kim Y.S., Kim K.Y., Lee W.B., Suh Y.H., and Kim S.S. C-terminal fragment of amyloid precursor protein induces astrocytosis. J. Neurochem. 78 (2001) 109-120
13. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., and Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 (1999) 585-595
14. Barger S.W., and Harmon A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388 (1997) 878-881
15. Barger S.W., Smithswintosky V.L., Rydel R.E., and Mattson M.P. Beta-amyloid precursor protein mismetabolism and loss of calcium homeostasis in Alzheimers-disease. Alzheimers Dis.: Amyloid Precursor Proteins Signal Transduct. Neuronal Transplant. 695 (1993) 158-164
16. Barger S.W., Horster D., Furukawa K., Goodman Y., Krieglstein J., and Mattson M.P. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9328-9332
17. Bate C., Veerhuis R., Eikelenboom P., and Williarns A. Microglia kill amyloid-beta1-42 damaged neurons by a CD14-dependent process. Neuroreport 15 (2004) 1427-1430
18. Bauer M.K., Lieb K., Schulze-Osthoff K., Berger M., Gebicke-Haerter P.J., Bauer J., and Fiebich B.L. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem. 243 (1997) 726-731
19. Beard C.M., Waring S.C., O'Brien P.C., Kurland L.T., and Kokmen E. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin. Proc. 73 (1998) 951-955
20. Beglopoulos V., Sun X., Saura C.A., Lemere C.A., Kim R.D., and Shen J. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J. Biol. Chem. 279 (2004) 46907-46914
21. Benveniste E.N., Nguyen V.T., and O'Keefe G.M. Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem. Int. 39 (2001) 381-391
22. Benzing W.C., Wujek J.R., Ward E.K., Shaffer D., Ashe K.H., Younkin S.G., and Brunden K.R. Evidence for glial-mediated inflammation in aged APPSW transgenic mice. Neurobiol. Aging 20 (1999) 581-589
23. Bezzi P., Domercq M., Brambilla L., Galli R., Schols D., De Clercq E., Vescovi A., Bagetta G., Kollias G., Meldolesi J., and Volterra A. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci. 4 (2001) 702-710
24. Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C., and Andreasson K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 56 (2004) 240-248
25. Blasko I., Marx F., Steiner E., Hartmann T., and Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 13 (1999) 63-68
26. Blasko I., Veerhuis R., Stampfer-Kountchev M., Saurwein-Teissl M., Eikelenboom P., and Grubeck-Loebenstein B. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol. Dis. 7 (2000) 682-689
27. Blasko I., Apochal A., Boeck G., Hartmann T., Grubeck-Loebenstein B., and Ransmayr G. Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol. Dis. 8 (2001) 1094-1101
28. Blasko I., Beer R., Bigl M., Apelt J., Franz G., Rudzki D., Ransmayr G., Kampfl A., and Schliebs R. Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase BACE-1. J. Neural Transm. 111 (2004) 523-536
29. Boje K.M., and Arora P.K. Microglial-produced nitric-oxide and reactive nitrogen-oxides mediate neuronal cell-death. Brain Res. 587 (1992) 250-256
30. Bondareff W., Mountjoy C.Q., Roth M., Rossor M.N., Iversen L.L., Reynolds G.P., and Hauser D.L. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1 (1987) 256-262
31. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., Wang H., Abumrad N., Eaton J.W., and Tracey K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000) 458-462
32. Botchkina G.I., Meistrell III M.E., Botchkina I.L., and Tracey K.J. Expression of TNF and TNF receptors p55 and p75 in the rat brain after focal cerebral ischemia. Mol. Med. 3 (1997) 765-781
33. Botto M. C1q knock-out mice for the study of complement deficiency in autoimmune disease. Exp. Clin. Immunogenet. 15 (1998) 231-234
34. Braak H., and Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Transm., Suppl. 53 (1998) 127-140
35. Braida D., Sacerdote P., Panerai A.E., Bianchi M., Aloisi A.M., Iosue S., and Sala M. Cognitive function in young and adult IL interleukin-6 deficient mice. Behav. Brain Res. 153 (2004) 423-429
36. Breder C.D., Tsujimoto M., Terano Y., Scott D.W., and Saper C.B. Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J. Comp. Neurol. 337 (1993) 543-567
37. Bredt D.S., and Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 682-685
38. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 (2002) 615-624
39. Breitner J.C. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol. Aging 17 (1996) 789-794
40. Breitner J.C., and Zandi P.P. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease?. N. Engl. J. Med. 345 (2001) 1567-1568
41. Breitner J.C., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., Pericak-Vance M.A., and Saunders A.M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16 (1995) 523-530
42. Brown G.C., and Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol. 27 (2003) 325-355
43. Brunkan A.L., and Goate A.M. Presenilin function and gamma-secretase activity. J. Neurochem. 93 (2005) 769-792
44. Butovsky O., Talpalar A.E., Ben Yaakov K., and Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell. Neurosci. 29 (2005) 381-393
45. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Jones T., and Banati R.B. In-vivo measurement of activated microglia in dementia. Lancet 358 (2001) 461-467
46. Candelario-Jalil E., Gonzalez-Falcon A., Garcia-Cabrera M., Alvarez D., Al Dalain S., Martinez G., Leon O.S., and Springer J.E. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J. Neurochem. 86 (2003) 545-555
47. Castell J.V., Andus T., Kunz D., and Heinrich P.C. Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat. Ann. N. Y. Acad. Sci. 557 (1989) 87-99 discussion 100-1, 87-99
48. Chao C.C., Hu S., Sheng W.S., Bu D., Bukrinsky M.I., and Peterson P.K. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 16 (1996) 276-284
49. Charo I.F., and Ransohoff R.M. Mechanisms of disease-the many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
50. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 (2001) 48-52
51. Chong Y. Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. Life Sci. 61 (1997) 2323-2333
52. Ciesielski-Treska J., Ulrich G., Aunis D., and Bader M.F. Chromogranin A triggers the expression of neurotoxic phenotype in microglia and induces apoptosis in neuronal/microglial cocultures. Eur. J. Neurosci. 10 (1998) 164
53. Ciesielski-Treska J., Ulrich G., Taupenot L., Chasserot-Golaz S., Corti A., Aunis D., and Bader M.F. Chromogranin A induces a neurotoxic phenotype in brain microglial cells. J. Biol. Chem. 273 (1998) 14339-14346
54. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., and Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20 (2000) 558-567
55. Combs C.K., Karlo J.C., Kao S.C., and Landreth G.E. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21 (2001) 1179-1188
56. Conde J.R., and Streit W.J. Microglia in the aging brain. J. Neuropathol. Exp. Neurol. 65 (2006) 199-203
57. Corradin S.B., Mauel J., Donini S.D., Quattrocchi E., and Ricciardi-Castagnoli P. Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia 7 (1993) 255-262
58. Cunard R., Eto Y., Muljadi J.T., Glass C.K., Kelly C.J., and Ricote M. Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J. Immunol. 172 (2004) 7530-7536
59. D'Andrea M.R., Cole G.M., and Ard M.D. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 25 (2004) 675-683
60. Davis S., and Laroche S. What can rodent models tell us about cognitive decline in Alzheimer's disease?. Mol. Neurobiol. 27 (2003) 249-276
61. Dawson V.L., Brahmbhatt H.P., Mong J.A., and Dawson T.M. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 33 (1994) 1425-1430
62. Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev., Immunol. 2 (2002) 748-759
63. DeGiorgio L.A., Shimizu Y., Chun H.S., Cho B.P., Sugama S., Joh T.H., and Volpe B.T. APP knockout attenuates microglial activation and enhances neuron survival in substantia nigra compacta after axotomy. Glia 38 (2002) 174-178
64. Dehmer T., Heneka M.T., Sastre M., Dichgans J., and Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88 (2004) 494-501
65. del Zoppo G., Ginis I., Hallenbeck J.M., Iadecola C., Wang X., and Feuerstein G.Z. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 10 (2000) 95-112
66. Demerle-Pallardy C., Lonchampt M.O., Chabrier P.E., and Braquet P. Nitric oxide synthase induction in glial cells: effect on neuronal survival. Life Sci. 52 (1993) 1883-1890
67. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta12,14-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168 (2002) 2508-2515
68. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.H., and Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7 (1993) 75-83
69. Du Y.S., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., Rajavashisth T., Chen X., Godman G.C., Stern D., and Schmidt A.M. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5296-5301
70. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B.A., and Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12 (1998) 1063-1073
71. Eikelenboom P., and van Gool W.A. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J. Neural Transm. 111 (2004) 281-294
72. Eikelenboom P., and Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 17 (1996) 673-680
73. Eikelenboom P., Zhan S.S., van Gool W.A., and Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15 (1994) 447-450
74. Eriksen J.L., Sagi S.A., Smith T.E., Weggen S., Das P., McLendon D.C., Ozols V.V., Jessing K.W., Zavitz K.H., Koo E.H., and Golde T.E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112 (2003) 440-449
75. Etminan M., Gill S., and Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 19 327 (2003) 128
76. Fassbender K., Walter S., Kuhl S., Landmann R., Ishii K., Bertsch T., Stalder A.K., Muehlhauser F., Liu Y., Ulmer A.J., Rivest S., Lentschat A., Gulbins E., Jucker M., Staufenbiel M., Brechtel K., Walter J., Multhaup G., Penke B., Adachi Y., Hartmann T., and Beyreuther K. The LPS receptor CD14 links innate immunity with Alzheimer's disease. FASEB J. 17 (2003)
77. Feinstein D.L., Galea E., Gavrilyuk V., Brosnan C.F., Whitacre C.C., Dumitrescu-Ozimek L., Landreth G.E., Pershadsingh H.A., Weinberg G., and Heneka M.T. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51 (2002) 694-702
78. Feinstein D.L., Heneka M.T., Gavrilyuk V., Dello R.C., Weinberg G., and Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 41 (2002) 357-365
79. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., and Russo C.D. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem. Pharmacol. 70 (2005) 177-188
80. Fetler L., and Amigorena S. Neuroscience. Brain under surveillance: the microglia patrol. Science 309 (2005) 392-393
81. Feuerstein G.Z., Liu T., and Barone F.C. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc. Brain Metab. Rev. 6 (1994) 341-360
82. Fiebich B.L., Schleicher S., Spleiss O., Czygan M., and Hull M. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C. J. Neurochem. 79 (2001) 950-958
83. Fishel M.A., Watson G.S., Montine T.J., Wang Q., Green P.S., Kulstad J.J., Cook D.G., Peskind E.R., Baker L.D., Goldgaber D., Nie W., Asthana S., Plymate S.R., Schwartz M.W., and Craft S. Hyperinsulinemia provokes synchronous increases in central inflammation and β-amyloid in normal adults. Arch. Neurol. 62 (2005) 1539-1544
84. Floden A.M., and Combs C.K. Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J. Neurosci. 26 (2006) 4644-4648
85. Fonseca M.I., Zhou J., Botto M., and Tenner A.J. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24 (2004) 6457-6465
86. Forno L.S. Pathology of Parkinsonism. J. Neurosurg. (1966) 266-271
87. Frautschy S.A., Yang F., Irrizarry M., Hyman B., Saido T.C., Hsiao K., and Cole G.M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 152 (1998) 307-317
88. Freedman R., Foote S.L., and Bloom F.E. Histochemical characterization of a neocortical projection of the nucleus locus coeruleus in the squirrel monkey. J. Comp. Neurol. 164 (1975) 209-231
89. Frei K., Nohava K., Malipiero U.V., Schwerdel C., and Fontana A. Production of macrophage colony-stimulating factor by astrocytes and brain macrophages. J. Neuroimmunol. 40 (1992) 189-196
90. Fritschy J.M., and Grzanna R. Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience 30 (1989) 181-197
91. Galea E., Feinstein D.L., and Reis D.J. Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10945-10949
92. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
93. Gasque P., Fontaine M., and Morgan B.P. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154 (1995) 4726-4733
94. Gavrilyuk V., Dello R.C., Heneka M.T., Pelligrino D., Weinberg G., and Feinstein D.L. Norepinephrine increases I kappa B alpha expression in astrocytes. J. Biol. Chem. 277 (2002) 29662-29668
95. German D.C., Manaye K.F., White III C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., and Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32 (1992) 667-676
96. Glabinski A.R., and Ransohoff R.M. Chemokines and chemokine receptors in CNS pathology. J. Neurovirology 5 (1999) 3-12
97. Gong C., Qin Z., Betz A.L., Liu X.H., and Yang G.Y. Cellular localization of tumor necrosis factor alpha following focal cerebral ischemia in mice. Brain Res. 801 (1998) 1-8
98. Graham A.J., Ray M.A., Perry E.K., Jaros E., Perry R.H., Volsen S.G., Bose S., Evans N., Lindstrom J., and Court J.A. Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J. Chem. Neuroanat. 25 (2003) 97-113
99. Grammas P., and Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol. Aging 22 (2001) 837-842
100. Griffin W.S.T. IL-1 and the cytokine cycle in Alzheimer's disease. J. Neurochem. 74 (2000) S52
101. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., and Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 8 (1998) 65-72
102. Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D.C., Mesulam, M.M., in press. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging. (Mar 27, Electronic publication ahead of print. doi:10.1016/j.neurobiolaging.2006.02.007).
103. Guo J.T., Yu J., Grass D., de Beer F.C., and Kindy M.S. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J. Neurosci. 22 (2002) 5900-5909
104. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
105. Hanisch U.K. Microglia as a source and target of cytokines. Glia 40 (2002) 140-155
106. Hardy J., and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12 (1991) 383-388
107. Hartlage-Rubsamen M., Zeitschel U., Apelt J., Gartner U., Franke H., Stahl T., Gunther A., Schliebs R., Penkowa M., Bigl V., and Rossner S. Astrocytic expression of the Alzheimer's disease beta-secretase BACE1 is stimulus-dependent. Glia 41 (2003) 169-179
108. Heneka M.T., and Feinstein D.L. Expression and function of inducible nitric oxide synthase in neurons. J. Neuroimmunol. 114 (2001) 8-18
109. Heneka M.T., Loschmann P.A., Gleichmann M., Weller M., Schulz J.B., Wullner U., and Klockgether T. Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. J. Neurochem. 71 (1998) 88-94
110. Heneka M.T., Feinstein D.L., Galea E., Gleichmann M., Wullner U., and Klockgether T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100 (1999) 156-168
111. Heneka M.T., Klockgether T., and Feinstein D.L. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 20 (2000) 6862-6867
112. Heneka M.T., Wiesinger H., Dumitrescu-Ozimek L., Riederer P., Feinstein D.L., and Klockgether T. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 906-916
113. Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Weinberg G., Klockgether T., and Feinstein D.L. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22 (2002) 2434-2442
114. Heneka M.T., Gavrilyuk V., Landreth G.E., O'Banion M.K., Weinberg G., and Feinstein D.L. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J. Neurochem. 85 (2003) 387-398
115. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Dewachter I., Walter J., Klockgether T., and Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J. Neuroinflam. 2 (2005) 22
116. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., and Landreth G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
117. Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., Sastre M., Galldiks N., Zimmer A., Hoehn M., Heiss W.D., Klockgether T., and Staufenbiel M. Locus Ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26 (2006) 1343-1354
118. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., and Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free-radical generation by the peptide - relevance to Alzheimer-disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3270-3274
119. Hesselgesser J., and Horuk R. Chemokine and chemokine receptor expression in the central nervous system. J. Neurovirology 5 (1999) 13-26
120. Hewett S.J., Csernansky C.A., and Choi D.W. Selective potentiation of NMDA-induced neuronal injury following induction of astrocytic iNOS. Neuron 13 (1994) 487-494
121. Heyser C.J., Masliah E., Samimi A., Campbell I.L., and Gold L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 1500-1505
122. Ho L., Purohit D., Haroutunian V., Luterman J.D., Willis F., Naslund J., Buxbaum J.D., Mohs R.C., Aisen P.S., and Pasinetti G.M. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch. Neurol. 58 (2001) 487-492
123. Ho G.J., Drego R., Hakimian E., and Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr. Drug Targets Inflamm. Allergy 4 (2005) 247-256
124. Hoozemans J.J.M., Rozemuller A.J.M., Janssen I., De Groot C.J.A., Veerhuis R., and Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 101 (2001) 2-8
125. Hoozemans J., Veerhuis R., Rozemuller A., Arendt T., and Eikelenboom P. Neuronal immunoreactivity for COX-2 and phosphorylation of prb precede P38 MAPK activation and neurofibrillary changes in ad temporal cortex. Neurobiol. Aging 25 (2004) S416
126. Hori K., Burd P.R., Furuke K., Kutza J., Weih K.A., and Clouse K.A. Human immunodeficiency virus-1-infected macrophages induce inducible nitric oxide synthase and nitric oxide NO production in astrocytes: astrocytic NO as a possible mediator of neural damage in acquired immunodeficiency syndrome. Blood 93 (1999) 1843-1850
127. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15 (1995) 1203-1218
128. Hu J.G., Akama K.T., Krafft G.A., Chromy B.A., and Van Eldik L.J. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res. 785 (1998) 195-206
129. In t'Veld, Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., and Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345 (2001) 1515-1521
130. Ishizuka K., Kimura T., Igata-yi R., Katsuragi S., Takamatsu J., and Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin. Neurosci. 51 (1997) 135-138
131. Itagaki S., McGeer P.L., Akiyama H., Zhu S., and Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer-disease. J. Neuroimmunol. 24 (1989) 173-182
132. Iversen L.L., Rossor M.N., Reynolds G.P., Hills R., Roth M., Mountjoy C.Q., Foote S.L., Morrison J.H., and Bloom F.E. Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci. Lett. 19 39 (1983) 95-100
133. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
134. Kalaria R.N., Andorn A.C., Tabaton M., Whitehouse P.J., Harik S.I., and Unnerstall J.R. Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J. Neurochem. 53 (1989) 1772-1781
135. *4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat. Genet. 10 (1995) 486-488
136. Kawano T., Anrather J., Zhou P., Park L., Wang G., Frys K.A., Kunz A., Cho S.H., Orio M., and Iadecola C. Prostaglandin E-2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med. 12 (2006) 225-229
137. Kelley K.A., Ho L., Winger D., Freire-Moar J., Borelli C.B., Aisen P.S., and Pasinetti G.M. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am. J. Pathol. 155 (1999) 995-1004
138. Kelly D., Campbell J.I., King T.P., Grant G., Jansson E.A., Coutts A.G., Pettersson S., and Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat. Immunol. 5 (2004) 104-112
139. Kim S.U., Nagai A., Nakagawa E., Hatori K., Choi H.B., and Lee M.A. Beta-amyloid up-regulates expression of cytokines and chemokines in human microglia and human microglia cell line. J. Neuropathol. Exp. Neurol. 60 (2001) 546
140. Kitamura Y., Shimohama S., Koike H., Kakimura J., Matsuoka Y., Nomura Y., Gebicke-Haerter P.J., and Taniguchi T. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254 (1999) 582-586
141. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., and Laferla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25 (2005) 8843-8853
142. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., Umesono K., and Evans R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U. S. A. 19;91 (1994) 7355-7359
143. Koistinaho M., Lin S.Z., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K.R., and Paul S.M. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 10 (2004) 719-726
144. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 (1996) 312-318
145. Lamb B.T., Bardel K.A., Kulnane L.S., Anderson J.J., Holtz G., Wagner S.L., Sisodia S.S., and Hoeger E.J. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat. Neurosci. 2 (1999) 695-697
146. Landreth G.E., and Heneka M.T. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol. Aging 22 (2001) 937-944
147. Lee S.C., Collins M., Vanguri P., and Shin M.L. Glutamate differentially inhibits the expression of class II MHC antigens on astrocytes and microglia. J. Immunol. 148 (1992) 3391-3397
148. Lee S.C., Zhao M.L., Hirano A., and Dickson D.W. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J. Neuropathol. Exp. Neurol. 58 (1999) 1163-1169
149. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001) 1121-1159
150. Lee Y.B., Nagai A., and Kim S.U. Cytokines, chemokines, and cytokine receptors in human microglia. J. Neurosci. Res. 69 (2002) 94-103
151. Lee E.O., Shin Y.J., and Chong Y.H. Mechanisms involved in prostaglandin E2-mediated neuroprotection against TNF-alpha: possible involvement of multiple signal transduction and beta-catenin/T-cell factor. J. Neuroimmunol. 155 (2004) 21-31
152. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272 (1997) 3406-3410
153. Li M., Pascual G., and Glass C.K. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20 (2000) 4699-4707
154. Li Y.K., Liu L., Barger S.W., and Griffin W.S.T. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23 (2003) 1605-1611
155. Liang X.B., Wang Q., Hand T., Wu L.J., Breyer R.M., Montine T.J., and Andreasson K. Deletion of the prostaglandin E-2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J. Neurosci. 25 (2005) 10180-10187
156. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., and Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20 (2000) 5709-5714
157. Lim G.P., Yang F., Chu T., Gahtan E., Ubeda O., Beech W., Overmier J.B., Hsiao-Ashec K., Frautschy S.A., and Cole G.M. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22 (2001) 983-991
158. Lindberg C., Selenica M.L.B., Westlind-Danielsson A., and Schultzberg M. beta-amyloid protein structure determines the nature of cytokine release from rat microglia. J. Mol. Neurosci. 27 (2005) 1-12
159. Liu B., and Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304 (2003) 1-7
160. Lleo A., Berezovska O., Herl L., Raju S., Deng A., Bacskai B.J., Frosch M.P., Irizarry M., and Hyman B.T. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med. 10 (2004) 1065-1066
161. Lue L.F., Rydel R., Brigham E.F., Yang L.B., Hampel H., Murphy G.M., Brachova L., Yan S.D., Walker D.G., Shen Y., and Rogers J. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35 (2001) 72-79
162. Lue L.F., Walker D.G., and Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol. Aging 22 (2001) 945-956
163. Lukiw W.J., and Bazan N.G. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res. 50 (1997) 937-945
164. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338 (1998) 436-445
165. Ma J.Y., Yee A., Brewer H.B., Das S., and Potter H. Amyloid-associated proteins alpha1-antichymotrypsin and apolipoprotein-e promote assembly of Alzheimer beta-protein into filaments. Nature 372 (1994) 92-94
166. Mackenzie I.R. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation. Neurobiol. Aging 22 (2001) 819-822
167. Mackenzie I.R., and Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50 (1998) 986-990
168. Magnuson D.S., Staines W.A., and Marshall K.C. Electrophysiological changes accompanying DSP-4 lesions of rat locus coeruleus neurons. Brain Res. 19 628 (1993) 317-320
169. Mann D.M., Lincoln J., Yates P.O., Stamp J.E., and Toper S. Changes in the monoamine containing neurones of the human CNS in senile dementia. Br. J. Psychiatry 136 (1980) 533-541
170. Mann D.M., Yates P.O., and Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J. Neurol. Neurosurg. Psychiatry 45 (1982) 113-119
171. Marcyniuk B., Mann D.M., and Yates P.O. The topography of cell loss from locus caeruleus in Alzheimer's disease. J. Neurol. Sci. 76 (1986) 335-345
172. Marien M.R., Colpaert F.C., and Rosenquist A.C. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain. Res. Brain Res. Rev. 45 (2004) 38-78
173. Mattson M.P. ways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
174. Mavridis M., Degryse A.D., Lategan A.J., Marien M.R., and Colpaert F.C. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41 (1991) 507-523
175. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., Breyer R.M., and Andreasson K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24 (2004) 257-268
176. McCusker S.M., Curran M.D., Dynan K.B., McCullagh C.D., Urquhart D.D., Middleton D., Patterson C.C., McIlroy S.P., and Passmore A.P. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 357 (2001) 436-439
177. McGeer P.L., and McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain. Res. Brain Res. Rev. 21 (1995) 195-218
178. McGeer P.L., and McGeer E.G. The possible role of complement activation in Alzheimer disease. Trends Mol. Med. 8 (2002) 519-523
179. McGeer P.L., Schulzer M., and McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 (1996) 425-432
180. Mehlhorn G., Hollborn M., and Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 18 (2000) 423-431
181. Minghetti L., Polazzi E., Nicolini A., Creminon C., and Levi G. Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drugs. Eur. J. Neurosci. 9 (1997) 934-940
182. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Haute C.V., Checler F., Godaux E., Cordell B., and Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274 (1999) 6483-6492
183. Moncada C., Lekieffre D., Arvin B., and Meldrum B. Effect of NO synthase inhibition on NMDA- and ischaemia-induced hippocampal lesions. Neuroreport 3 (1992) 530-532
184. Montine T.J., Sidell K.R., Crews B.C., Markesbery W.R., Marnett L.J., Roberts L.J., and Morrow J.D. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53 (1999) 1495-1498
185. Moore A.H., Olschowka J.A., Williams J.P., Okunieff P., and O'Banion M.K. Regulation of prostaglandin E-2 synthesis after brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 267-272
186. Mori K., Togashi H., Ueno K., Matsumoto M., and Yoshioka M. Aminoguanidine prevented the impairment of learning behavior and hippocampal long-term potentiation following transient cerebral ischemia. Behav. Brain Res. 120 (2001) 159-168
187. Morihara T., Teter B., Yang F., Lim G.P., Boudinot S., Boudinot F.D., Frautschy S.A., and Cole G.M. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid Abeta pathology in Alzheimer's models. Neuropsychopharmacology 30 (2005) 1111-1120
188. Morimoto K., Murasugi T., and Oda T. Acute neuroinflammation exacerbates excitotoxicity in rat hippocampus in vivo. Exp. Neurol. 177 (2002) 95-104
189. Mrak R.E., and Griffin W.S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol. Aging 22 (2001) 903-908
190. Murphy P.G., Borthwick L.S., Johnston R.S., Kuchel G., and Richardson P.M. Nature of the retrograde signal from injured nerves that induces interleukin-6 mRNA in neurons. J. Neurosci. 19 (1999) 3791-3800
191. Murray C.A., and Lynch M.A. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J. Neurosci. 18 (1998) 2974-2981
192. Nagatsu T., and Sawada M. Inflammatory process in Parkinson's disease: Role for cytokines. Curr. Pharm. Des. 11 (2005) 999-1016
193. Nagele R.G., D'Andrea M.R., Lee H., Venkataraman V., and Wang H.Y. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 971 (2003) 197-209
194. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79 (1999) 1193-1226
195. Natarajan C., and Bright J.J. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun. 3 (2002) 59-70
196. Nicoll J.A., Mrak R.E., Graham D.I., Stewart J., Wilcock G., MacGowan S., Esiri M.M., Murray L.S., Dewar D., Love S., Moss T., and Griffin W.S. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neurol. 47 (2000) 365-368
197. Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., and Onoe K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J. Neuroimmunol. 116 (2001) 40-48
198. Nishino K., Lin C.S., Morse J.K., and Davis J.N. DSP4 treatment worsens hippocampal pyramidal cell damage after transient ischemia. Neuroscience 43 (1991) 361-367
199. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
200. O'Banion M.K. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol. 13 (1999) 45-82
201. O'Banion M.K., Miller J.C., Chang J.W., Kaplan M.D., and Coleman P.D. Interleukin-1 beta induces prostaglandin G/H synthase-2 cyclooxygenase-2 in primary murine astrocyte cultures. J. Neurochem. 66 (1996) 2532-2540
202. O'Banion M.K., Chang J.W., and Coleman P.D. Decreased expression of prostaglandin G/H synthase-2 PGHS-2 in Alzheimer's disease brain. Adv. Exp. Med. Biol. 407 (1997) 171-177
203. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and Laferla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A beta and synaptic dysfunction. Neuron 39 (2003) 409-421
204. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., and Laferla F.M. Temporal profile of amyloid-beta A beta oligomerization in an in vivo model of Alzheimer disease - a link between A beta and tau pathology. J. Biol. Chem. 281 (2006) 1599-1604
205. Oka A., and Takashima S. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 8 (1997) 1161-1164
206. Olpe H.R., Laszlo J., Dooley D.J., Heid J., and Steinmann M.W. Decreased activity of locus coeruleus neurons in the rat after DSP-4 treatment. Neurosci. Lett. 40 (1983) 81-84
207. Orzylowska O., Oderfeld-Nowak B., Zaremba M., Januszewski S., and Mossakowski M. Prolonged and concomitant induction of astroglial immunoreactivity of interleukin-1beta and interleukin-6 in the rat hippocampus after transient global ischemia. Neurosci. Lett. 263 (1999) 72-76
208. Osaka H., Mukherjee P., Aisen P.S., and Pasinetti G.M. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J. Cell. Biochem. 73 (1999) 303-311
209. Owens T., Babcock A.A., Millward J.M., and Toft-Hansen H. Cytokine and chemokine inter-regulation in the inflamed or injured CNS. Brain Res. Brain Res. Rev. 48 (2005) 178-184
210. Papassotiropoulos A., Bagli M., Jessen F., Bayer T.A., Maier W., Rao M.L., and Heun R. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann. Neurol. 45 (1999) 666-668
211. Paresce D.M., Ghosh R.N., and Maxfield F.R. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 17 (1996) 553-565
212. Pasinetti G.M., Tocco G., Sakhi S., Musleh W.D., DeSimoni M.G., Mascarucci P., Schreiber S., Baudry M., and Finch C.E. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol. Dis. 3 (1996) 197-204
213. Patsouris D., Muller M., and Kersten S. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance. Curr. Opin. Investig. Drugs 5 (2004) 1045-1050
214. Pavlov V.A., and Tracey K.J. The cholinergic anti-inflammatory pathway. Brain Behav. Immun. 19 (2005) 493-499
215. Perry R.T., Collins J.S., Harrell L.E., Acton R.T., and Go R.C. Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. Am. J. Med. Genet. 105 (2001) 332-342
216. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., and Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11294-11298
217. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., and Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273 (1998) 32730-32738
218. Rangon C.M., Haik S., Faucheux B.A., Metz-Boutigue M.H., Fierville F., Fuchs J.P., Hauw J.J., and Aunis D. Different chromogranin immunoreactivity between prion and a-beta amyloid plaque. Neuroreport 14 (2003) 755-758
219. Ray I., Chauhan A., Wisniewski H.M., Wegiel J., Kim K.S., and Chauhan V.P. Binding of amyloid beta-protein to intracellular brain proteins in rat and human. Neurochem. Res. 23 (1998) 1277-1282
220. Reines S.A., Block G.A., Morris J.C., Liu G., Nessly M.L., Lines C.R., Norman B.A., and Baranak C.C. Rofecoxib - no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 (2004) 66-71
221. Rich J.B., Rasmusson D.X., Folstein M.F., Carson K.A., Kawas C., and Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45 (1995) 51-55
222. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
223. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. 82 (2004) 510-529
224. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., and Lieberburg I. Complement activation by beta-amyloid in Alzheimer-disease. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10016-10020
225. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43 (1993) 1609-1611
226. Rogers J.T., Leiter L.M., McPhee J., Cahill C.M., Zhan S.S., Potter H., and Nilsson L.N. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J. Biol. Chem. 274 (1999) 6421-6431
227. Rossi F., and Bianchini E. Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Biochem. Biophys. Res. Commun. 225 (1996) 474-478
228. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I kappa B kinase. Nature 403 (2000) 103-108
229. Rossner S., Lange-Dohna C., Zeitschel U., and Perez-Polo J.R. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. J. Neurochem. 92 (2005) 226-234
230. Rota E., Bellone G., Rocca P., Bergamasco B., Emanuelli G., and Ferrero P. Increased intrathecal TGF-beta 1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 27 (2006) 33-39
231. Rozemuller J.M., Eikelenboom P., Pals S.T., and Stam F.C. Microglial cells around amyloid plaques in Alzheimers-disease express leukocyte adhesion molecules of the Lfa-1 family. Neurosci. Lett. 101 (1989) 288-292
232. Rozemuller J.M., Eikelenboom P., Stam F.C., Beyreuther K., and Masters C.L. A4-protein in Alzheimers-disease - primary and secondary cellular events in extracellular amyloid deposition. J. Neuropathol. Exp. Neurol. 48 (1989) 674-691
233. Sastre M., Dewachter I., Landreth G.E., Willson T.M., Klockgether T., Van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23 (2003) 9796-9804
234. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., Van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPAR gamma. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 443-448
235. Schubert P., Morino T., Miyazaki H., Ogata T., Nakamura Y., Marchini C., and Ferroni S. Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann. N. Y. Acad. Sci. 903 (2000) 24-33
236. Selkoe D.J. Toward a remembrance of things past: deciphering Alzheimer disease. Harvey Lect. 99 (2003) 23-45
237. Selkoe D.J. Defining molecular targets to prevent Alzheimer disease. Arch. Neurol. 62 (2005) 192-195
238. Selmaj K.W., Farooq M., Norton W.T., Raine C.S., and Brosnan C.F. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J. Immunol. 144 (1990) 129-135
239. Semmler A., Okulla T., Sastre M., Dumitrescu-Ozimek L., and Heneka M.T. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J. Chem. Neuroanat. 30 (2005) 144-157
240. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 (1992) 325-327
241. Shen Y., and Meri S. Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog. Neurobiol. 70 (2003) 463-472
242. Sheng J.G., Zhu S.G., Jones R.A., Griffin W.S.T., and Mrak R.E. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol. 163 (2000) 388-391
243. Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L., and Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol. Dis. 14 (2003) 133-145
244. Shie F.S., Breyer R.M., and Montine T.J. Microglia lacking E prostanoid receptor subtype 2 have enhanced abeta phagocytosis yet lack abeta-activated neurotoxicity. Am. J. Pathol. 166 (2005) 1163-1172
245. Shie F.S., Montine K.S., Breyer R.M., and Montine T.J. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 52 (2005) 70-77
246. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B., et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258 (1992) 126-129
247. Simard A.R., Soulet D., Gowing G., Julien J.P., and Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49 (2006) 489-502
248. Simmons M.L., and Murphy S. Induction of nitric oxide synthase in glial cells. J. Neurochem. 59 (1992) 897-905
249. Skaper S.D., Facci L., and Leon A. Inflammatory mediator stimulation of astrocytes and meningeal fibroblasts induces neuronal degeneration via the nitridergic pathway. J. Neurochem. 64 (1995) 266-276
250. Slawik H., Volk B., Fiebich B., and Hull M. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem. Int. 45 (2004) 653-660
251. Sly L.M., Krzesicki R.F., Brashler J.R., Buhl A.E., McKinley D.D., Carter D.B., and Chin J.E. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. Bull. 56 (2001) 581-588
252. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17 (1997) 2653-2657
253. Smithswintosky V.L., Pettigrew L.C., Craddock S.D., Culwell A.R., Rydel R.E., and Mattson M.P. Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J. Neurochem. 63 (1994) 781-784
254. Smits H.A., Rijsmus A., van Loon J.H., Wat J.W.Y., Verhoef J., Boven L.A., and Nottet H.S.L.M. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 127 (2002) 160-168
255. Snyder S.W., Wang G.T., Barrett L., Ladror U.S., Casuto D., Lee C.M., Krafft G.A., Holzman R.B., and Holzman T.F. Complement C1Q does not bind monomeric beta-amyloid. Exp. Neurol. 128 (1994) 136-142
256. Stalder A.K., Carson M.J., Pagenstecher A., Asensio V.C., Kincaid C., Benedict M., Powell H.C., Masliah E., and Campbell I.L. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient SCID mice with astrocyte-targeted expression of tumor necrosis factor. Am. J. Pathol. 153 (1998) 767-783
257. Stalder A.K., Ermini F., Bondolfi L., Krenger W., Burbach G.J., Deller T., Coomaraswamy J., Staufenbiel M., Landmann R., and Jucker M. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci. 25 (2005) 11125-11132
258. Stewart W.F., Kawas C., Corrada M., and Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 (1997) 626-632
259. Streit W.J., Conde J.R., Fendrick S.E., Flanary B.E., and Mariani C.L. Role of microglia in the central nervous system's immune response. Neurol. Res. 27 (2005) 685-691
260. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., Dzuiba J., Van Damme J., Walz A., Marriott D., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270 (1995) 27348-27357
261. Stuehr D.J., and Marletta M.A. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 7738-7742
262. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., and Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13287-13292
263. Sung S., Yang H., Uryu K., Lee E.B., Zhao L., Shineman D., Trojanowski J.Q., Lee V.M., and Pratico D. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am. J. Pathol. 165 (2004) 2197-2206
264. Suzuki S., Tanaka K., Nagata E., Ito D., Dembo T., and Fukuuchi Y. Cerebral neurons express interleukin-6 after transient forebrain ischemia in gerbils. Neurosci. Lett. 262 (1999) 117-120
265. Szczepanik A.M., Funes S., Petko W., and Ringheim G.E. IL-4, IL-10 and IL-13 modulate A beta1-42-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol. 113 (2001) 49-62
266. Szczepanik A.M., Rampe D., and Ringheim G.E. Amyloid-beta peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J. Neurochem. 77 (2001) 304-317
267. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., and Goodman S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23 (2004) 159-169
268. Takadera T., Shiraishi Y., and Ohyashiki T. Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem. Int. 45 (2004) 713-719
269. Tamagno E., Bardini P., Obbili A., Vitali A., Borghi R., Zaccheo D., Pronzato M.A., Danni O., Smith M.A., Perry G., and Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 10 (2002) 279-288
270. Tan J., Town T., Paris D., Mori T., Suo Z., Crawford F., Mattson M.P., Flavell R.A., and Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286 (1999) 2352-2355
271. Tancredi V., D'Arcangelo G., Grassi F., Tarroni P., Palmieri G., Santoni A., and Eusebi F. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci. Lett. 146 (1992) 176-178
272. Tancredi V., D'Antuono M., Cafe C., Giovedi S., Bue M.C., D'Arcangelo G., Onofri F., and Benfenati F. The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. J. Neurochem. 75 (2000) 634-643
273. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005) 545-555
274. Taupenot L., CiesielskiTreska J., Ulrich G., ChasserotGolaz S., Aunis D., and Bader M.F. Chromogranin a triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 72 (1996) 377-389
275. Taylor P.R., Carugati A., Fadok V.A., Cook H.T., Andrews M., Carroll M.C., Savill J.S., Henson P.M., Botto M., and Walport M.J. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192 (2000) 359-366
276. Tchelingerian J.L., Vignais L., and Jacque C. TNF alpha gene expression is induced in neurones after a hippocampal lesion. Neuroreport 5 (1994) 585-588
277. Teaktong T., Graham A., Court J., Perry R., Jaros E., Johnson M., Hall R., and Perry E. Alzheimer's disease is associated with a selective increase in alpha 7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 41 (2003) 207-211
278. Thal L.J., Ferris S.H., Kirby L., Block G.A., Lines C.R., Yuen E., Assaid C., Nessly M.L., Norman B.A., Baranak C.C., and Reines S.A. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30 (2005) 1204-1215
279. Thery C., Stanley E.R., and Mallat M. Interleukin-1 and tumor-necrosis-factor-alpha stimulate the production of colony-stimulating factor-I by murine astrocytes. J. Neurochem. 59 (1992) 1183-1186
280. Thiemermann C. The role of the l-arginine: nitric oxide pathway in circulatory shock. Adv. Pharmacol. 28 (1994) 45-79
281. Thomas T., Nadackal T.G., and Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 12 (2001) 3263-3267
282. Tocco G., Freire-Moar J., Schreiber S.S., Sakhi S.H., Aisen P.S., and Pasinetti G.M. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp. Neurol. 144 (1997) 339-349
283. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994) 1224-1234
284. Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., and Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11 (1992) 433-439
285. Tuppo E.E., and Arias H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37 (2005) 289-305
286. Vamecq J., and Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 354 (1999) 141-148
287. van Beek J., Elward K., and Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann. N. Y. Acad. Sci. 992 (2003) 56-71
288. Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van Den H.C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., Sciot R., and Van Leuven F. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am. J. Pathol. 157 (2000) 1283-1298
289. Veerhuis R., Boshuizen R.S., Morbin M., Mazzoleni G., Hoozemans J.J.M., Langedijk J.P.M., Tagliavini F., Langeveld J.P.M., and Eikelenboom P. Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q. Neurobiol. Dis. 19 (2005) 273-282
290. Vodovotz Y., Lucia M.S., Flanders K.C., Chesler L., Xie Q.W., Smith T.W., Weidner J., Mumford R., Webber R., Nathan C., Roberts A.B., Lippa C.F., and Sporn M.B. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. 184 (1996) 1425-1433
291. Wallace M.N., Geddes J.G., Farquhar D.A., and Masson M.R. Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Exp. Neurol. 144 (1997) 266-272
292. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
293. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
294. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002) 552-557
295. Walter J., Fluhrer R., Hartung B., Willem M., Kaether C., Capell A., Lammich S., Multhaup G., and Haass C. Phosphorylation regulates intracellular trafficking of beta-secretase. J. Biol. Chem. 276 (2001) 14634-14641
296. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Wang H.C., Yang H., Ulloa L., Al Abed Y., Czura C.J., and Tracey K.J. Nicotinic acetylcholine receptor alpha 7 subunit is an essential regulator of inflammation. Nature 421 (2003) 384-388
297. Wang Q., Rowan M.J., and Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 24 (2004) 6049-6056
298. Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K., Walker D.G., Bradt B., Cooper N.R., and Rogers J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18 (1997) 415-421
299. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., and Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 (2001) 212-216
300. Weldon D.T., Rogers S.D., Ghilardi J.R., Finke M.P., Cleary J.P., O'Hare E., Esler W.P., Maggio J.E., and Mantyh P.W. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci. 18 (1998) 2161-2173
301. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., and Ashe K.H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22 (2002) 1858-1867
302. White J.A., Manelli A.M., Holmberg K.H., Van Eldik L.J., and Ladu M.J. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol. Dis. 18 (2005) 459-465
303. Wilcock G.K., Esiri M.M., Bowen D.M., and Hughes A.O. The differential involvement of subcortical nuclei in senile dementia of Alzheimer's type. J. Neurol. Neurosurg. Psychiatry 51 (1988) 842-849
304. Willenborg D.O., Fordham S.A., Staykova M.A., Ramshaw I.A., and Cowden W.B. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J. Immunol. 163 (1999) 5278-5286
305. Willenborg D.O., Staykova M.A., and Cowden W.B. Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: a review. J. Neuroimmunol. 100 (1999) 21-35
306. Wyss-Coray T., Feng L., Masliah E., Ruppe M.D., Lee H.S., Toggas S.M., Rockenstein E.M., and Mucke L. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am. J. Pathol. 147 (1995) 53-67
307. Wyss-Coray T., Masliah E., Mallory M., McConlogue L., Johnson-Wood K., Lin C., and Mucke L. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 389 (1997) 603-606
308. Wyss-Coray T., Lin C., Sanan D.A., Mucke L., and Masliah E. Chronic overproduction of transforming growth factor-beta 1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am. J. Pathol. 156 (2000) 139-150
309. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., and Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10837-10842
310. Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., Silverstein S.C., and Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9 (2003) 453-457
311. Xia M.Q., and Hyman B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J. Neurovirology 5 (1999) 32-41
312. Xia M.Q., Qin S.X., Wu L.J., Mackay C.R., and Hyman B.T. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am. J. Pathol. 153 (1998) 31-37
313. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., and Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons-regulation by synaptic activity and glucocorticoids. Neuron 11 (1993) 371-386
314. Yan S.D., Yan S.F., Chen X., Fu J., Chen M., Kuppusamy P., Smith M.A., Perry G., Godman G.C., Nawroth P., et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat. Med. 1 (1995) 693-699
315. Yan S.D., Stern D., Kane M.D., Kuo Y.M., Lampert H.C., and Roher A.E. RAGE-A beta interactions in the pathophysiology of Alzheimer's disease. Restor. Neurol. Neurosci. 12 (1998) 167-173
316. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., and Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23 (2003) 7504-7509
317. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830 (1999) 226-236
318. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 154 (1999) 927-936
319. Yates C.M., Simpson J., Gordon A., Maloney A.F., Allison Y., Ritchie I.M., and Urquhart A. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res. 280 (1983) 119-126
320. Yermakova A., and O'Banion M.K. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr. Pharm. Des. 6 (2000) 1755-1776
321. Yermakova A.V., and O'Banion M.K. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol. Aging 22 (2001) 823-836
322. Yermakova A.V., Rollins J., Callahan L.M., Rogers J., and O'Banion M.K. Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neuropathol. Exp. Neurol. 58 (1999) 1135-1146
323. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
324. Zarow C., Lyness S.A., Mortimer J.A., and Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60 (2003) 337-341